Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?
What are useful clinical features that help differentiate mechanics hands from other conditions such as hand dermatitis or psoriasis?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
What are your vaccine recommendations while patients are on biologics?
How do you manage recalcitrant tumid lupus in a patient with partial response to antimalarials and off-label apremilast, in the setting of coexisting MDS with significant neutropenia?
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
